The list of FDA-approved antibodies for cancer therapy continues to expand, including ones against cell surface antigens, such as human epidermal growth factor receptor 2 (HER2), programmed-death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and CD20, as well as soluble proteins, such as vascular endothelial growth factor (VEGF) and TNF[37]. This evidence concerns the gene VEGFA and cancer.